Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 11/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828143 | 0.80 | UTS2R (0.42) | UTS2RALDH1A1LMNAMAPT | |
| SCHEMBL22828289 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| SCHEMBL22828141 | 0.78 | CHRNB2 (0.40) | ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL22828282 | 0.76 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTNPSR1TDP1 | |
| SCHEMBL22827991 | 0.76 | KDM4E (0.44) | ALDH1A1MAPT | |
| SCHEMBL22828287 | 0.75 | CHRNB2 (0.36) | ALDH1A1MAPT | |
| SCHEMBL22828288 | 0.73 | L3MBTL1 (0.44) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22828319 | 0.69 | PTGS2 (0.40) | ALDH1A1 | |
| SCHEMBL1274406 | 0.69 | RIPK1 (0.56) | GPR88RIPK1 | |
| SCHEMBL4564487 | 0.69 | RIPK1 (0.56) | GPR88RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | AZI2, AAAS, ZRANB2 | UTS2R 688/4885GPR88 2502/4885RIPK1 4617/4885 |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | AZI2, AAAS, ZRANB2 | UTS2R 688/4885GPR88 2502/4885RIPK1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.